Novel drug delivery systems.
In the last few years, research in the field of anticancer drug development has adopted a number of novel approaches. Some of these new therapies have already reached the clinic. These include drugs stimulating cytokine production, drugs affecting the cell cycle, monoclonal antibodies, anti-angiogenic compounds, gene therapy, antisense therapy and vaccines. These new targets and strategies for cancer treatment require new guidelines for preclinical research and for performing phase I and phase II trials. The identification of surrogate endpoints for efficacy in preclinical and clinical trials is a new challenge for both scientists and clinicians.
Raynaud
F
F
CRC Centre for Cancer Therapeutics, The Institute Of Cancer Research, Sutton, Surrey, SM2 5NG, UK. floren@icr.ac.uk